Adding rolapitant improves prevention of chemo-induced nausea, vomiting

the ONA take:

Rolapitant in combination with a 5-HT3 receptor antagonist and dexamethasone is well-tolerated and demonstrates superiority over active control for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the at-risk period following the administration of highly emetogenic cisplatin-based chemotherapy, a new study published online ahead of print in The Lancet Oncology has shown.

Two double-blind, active-controlled, phase 3 trials were conducted to assess rolapitant, a neurokinin-1 receptor antagonist, for the prevention of CINV in patients with cancer in the 120 hours after administration of cisplatin-based chemotherapy.

Patients were randomly assigned to receive either oral rolapitant 180 mg or placebo 1 to 2 hours before cisplatin in conjunction with granisetron and dexamethasone. Results showed that a significantly higher proportion of patients in the rolapitant arms achieved completes responses during the delayed phase than did patients who received placebo.

In regard to safety, no serious treatment-emergent adverse events were related to rolapitant treatment.

The findings suggest that adding rolapitant to granisetron and dexamethasone is superior to granisetron and dexamethasone alone for the prevention of CINV during the delayed phase after receiving cisplatin-based chemotherapy.

Adding rolapitant improves prevention of chemo-induced nausea, vomiting
Rolapitant demonstrates superiority over active control for the prevention of chemotherapy-induced nausea and vomiting.
Highly emetogenic chemotherapy induces emesis in almost all patients in the absence of prophylaxis. Guidelines recommend use of a neurokinin-1 (NK-1) receptor antagonist in conjunction with a 5-HT3 receptor antagonist and corticosteroid in patients receiving highly emetogenic chemotherapy.
READ FULL ARTICLE From Thelancet
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs